Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.66 |
| ▸ | NAMPT | P43490 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27927283 | 0.86 | EPHX2 (0.87) | RAB9ANPC1EPHX2CYP11B1CYP11B2 | |
| SCHEMBL791532 | 0.85 | LMNA (0.58) | RAB9ANPC1EPHX2CYP11B1CYP11B2 | |
| SCHEMBL9808115 | 0.80 | CYP11B1 (1.00) | RAB9ANPC1CYP11B1CYP11B2NAMPT | |
| SCHEMBL30582756 | 0.80 | CYP11B1 (1.00) | RAB9ANPC1CYP11B1CYP11B2NAMPT | |
| SCHEMBL7126678 | 0.80 | ROCK2 (0.64) | RAB9ANPC1EPHX2NAMPTLMNA | |
| SCHEMBL12977924 | 0.78 | CYP11B1 (0.66) | RAB9ANPC1EPHX2CYP11B1CYP11B2 | |
| SCHEMBL12978270 | 0.78 | RAB9A (0.74) | RAB9ANPC1EPHX2CYP11B1CYP11B2 | |
| SCHEMBL5435462 | 0.78 | NAMPT (0.76) | RAB9ANPC1CYP11B1CYP11B2NAMPT | |
| SCHEMBL3642636 | 0.78 | NAMPT (0.81) | RAB9ANPC1CYP11B1CYP11B2NAMPT | |
| SCHEMBL167081 | 0.78 | NAMPT (1.00) | RAB9ANPC1CYP11B1CYP11B2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | RAB9A 1806/4885NPC1 4631/4885EPHX2 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.